News for Jounce Therapeutics, Inc. (JNCE)

Tourmaline Bio appoints new CFO amid growth phase

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer...

Feb 23, 2023 / 01:00PM GMTOperator Good morning, and welcome to Jounce and Redx's recommended All-Share Merger Conference Call. At this time, all participants a

The PD-1 and PD-L1 inhibitor market is anticipated to be driven in the coming years due to the rise in novel drugs and therapies and the increase in...

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through...

SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel...

CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) (

Stockholders to Receive $1.85 Per Share in Cash Plus Contingent Value Rights...

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

Quince out-licensed COR588 and brought in an additional asset and then inexplicably ceased development. See why we recommend a sell on QNCE stock.

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 400 points on Wednesday. The Dow traded down 1.32% to 31,732.39 while the NASDAQ fell 0.24% to 11,400.70. The S&P 500, also fell, dropping, 1.11% to 3,875.80.

Read Reviewing Gilead Sciences (NASDAQ:GILD) and ERYTECH Pharma (NASDAQ:ERYP) at ETF Daily News

Read Investment Analysts’ Downgrades for May 11th (ACH, AMZN, AVYA, BHVN, BKFKF, CARE, CLVS, COIN, CS, CTSH) at ETF Daily News

Read Investment Analysts’ Upgrades for May 11th (ADDYY, AHT, ARCT, ARTNA, ARWR, ASHTY, AZEK, BNCDY, CELH, CLB) at ETF Daily News

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of understanding with Dhruva Space to expand its partnership to further the commercialization of space technologies and services.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Q4 2020 Earnings Conference Call February 25, 2021 08:00 ET Company Participants Malin Deon - Investor Relations Rich Murray - President & Chief...

Papa John’s International delivered lower-than-expected earnings in the fourth quarter. Meanwhile, shares of Papa John’s fell 7.4% in pre-market trading as the company posted earnings per share (EPS) of $0.40 during the fourth quarter, which were behind analysts’ expectations of $0.46. That said, revenue increased 12.5% year-on-year to $469.8 million, topping analysts’ estimates of $465.7 million. The increase in 4Q revenues was primarily attributable to higher comparable sales for North America restaurants, which saw 10.2% growth in company owned restaurants and 14.5% growth in franchised restaurants. Papa John’s (PZZA) international sales also increased on the back of higher commissary revenues and royalties resulting from comparable sales growth of 21.4%. For fiscal 2020, the company generated sales of $1.81 billion, up 12% from 2019. Diluted earnings per share came in at $1.40, versus $0.03 in the comparable year-ago period. Papa John’s President and CEO Rob Lynch said, “4Q was the third consecutive quarter of double-digit comparable sales growth and the sixth straight quarter of positive comparable sales in North America. We ended the year with the launch of Epic Stuffed Crust, the biggest product innovation in the company’s history, and our future is extremely bright.” In light of ongoing uncertainity about the future impact from the COVID-19 pandemic, Papa John’s did not provide any guidance. (See Papa John’s stock analysis on TipRanks) On Feb. 23, Deutsche Bank analyst Brian Mullan raised the price target to $110 (7.2% upside potential) from $91 and reiterated a Buy rating. Mullan believes the outlook for Papa John’s shares from here is favorable with a 12-month view. Turning to Wall Street, Papa John’s has a Strong Buy consensus rating based on 8 Buys and 1 Hold. The average analyst price target of $111.13 implies about 8.3% upside potential from current levels. Papa John’s stock has seen a runup of about 50% over the past year. Related News: Fisker Inks MOU With Foxconn To Develop EV; Shares Pop 22% Pre-Market Upwork Posts Better-Than-Expected 4Q Results; Shares Pop 18.7% After-Hours Nvidia Posts Better-Than-Expected 4Q Earnings; Street Remains Bullish More recent articles from Smarter Analyst: Jumia 4Q Revenues Miss Estimates, Losses Narrow To €40M Radian Group’s 4Q Earnings Beat Estimates; Street Sees 29% Upside Moderna Plans To Increase Supply Capacity For COVID-19 Vaccine; Shares Spike 5% Bilibili’s 4Q Sales Beat Analysts’ Estimates; Shares Rise 3.8%

- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination wi...